CTLA4 and osteosarcoma: Although the combination of two ICIs acting through different mechanisms, such as anti-CTLA4 and anti-PD-1, has shown synergy in preclinical models of osteosarcoma as well as in those of melanoma [40,45], such combinations have had mixed response so far in bone sarcomas.